Stock Blog Hub
Nov 25
Recently, Human Genome Sciences, Inc. (HGSI) and Aegera Therapeutics announced the initiation of dosing in a phase I clinical trial to evaluate the safety and tolerability of its lead inhibitor-of-apoptosis protein (IAP), HGS1029, as monotherapy...